The measurement of labor market entries with SOEP data: Introduction to the variable EINSTIEG_ARTK

The variable EINSTIEG_ARTK in the file BIOJOB indicates the wave of a first labor market entry. The variable refers to the entry into the labor market after the completion of education and apprenticeship. Since we account for all kinds of employment (full-time, parttime and marginal employment), such a definition captures the uncertainties and instabilities associated with the early career phase. At the same time, side-jobs or apprenticeships are explicitly assigned to the educational phase and excluded from the concept of labor market entry. Among the several plausible concepts and operationalization of labor market entries with SOEP data (among them the "age of first job"-variable), we consequently hold this indicator particularly suited for scholars who want to study the impact of labor market institutions on early career outcomes. As an alternative for researchers who do not rely on exact information on the transitional wave, we offer an alternative variable EINSTIEG_PBIO (that covers more cases, but is only exact on the basis of years, not waves)

Relaxation and overlap probability function in the spherical and mean spherical model

The problem of the equivalence of the spherical and mean spherical models, which has been thoroughly studied and understood in equilibrium, is considered anew from the dynamical point of view during the time evolution following a quench from above to below the critical temperature. It is found that there exists a crossover time $t^* \sim V^{2/d}$ such that for $t < t^*$ the two models are equivalent, while for $t > t^*$ macroscopic discrepancies arise. The relation between the off equilibrium response function and the structure of the equilibrium state, which usually holds for phase ordering systems, is found to hold for the spherical model but not for the mean spherical one. The latter model offers an explicit example of a system which is not stochastically stable.Comment: 11 pages, 1 figure, references corrected, to appear in Phys.Rev.

Computational results for an automatically tuned CMA-ES with increasing population size on the CEC&apos;05 benchmark set

Abstract In this article, we apply an automatic algorithm configuration tool to improve the performance of the CMA-ES algorithm with increasing population size (iCMA-ES), the best performing algorithm on the CEC&apos;05 benchmark set for continuous function optimization. In particular, we consider a separation between tuning and test sets and, thus, tune iCMA-ES on a different set of functions than the ones of the CEC&apos;05 benchmark set. Our experimental results show that the tuned iCMA-ES improves significantly over the default version of iCMA-ES. Furthermore, we provide some further analyses on the impact of the modified parameter settings on iCMA-ES performance and a comparison with recent results of algorithms that use CMA-ES as a subordinate local search

Nonperturbative Model Of Liouville Gravity

We obtain nonperturbative results in the framework of continuous Liouville theory. In particular, we express the specific heat ${\cal Z}$ of pure gravity in terms of an expansion of integrals on moduli spaces of punctured Riemann spheres. The integrands are written in terms of the Liouville action. We show that ${\cal Z}$ satisfies the Painlev\'e I.Comment: 11 pages, LaTex fil

A framework for operative and social sustainability functionalities in Human- Centric Cyber-Physical Production Systems

In a near future where manufacturing companies are faced with the rapid technological developments of Cyber-Physical Systems (CPS) and Industry 4.0, a need arises to consider how this will affect human operators remaining as a vital and important resource in modern production systems. What will the implications of these orchestrated and ubiquitous technologies in production – a concept we call Cyber-Physical Production Systems (CPPS) – be on the health, learning and operative performance of human workers? This paper makes three main contributions to address the question. First, it synthesizes the diverse literature regarding CPS and social sustainability in production systems. Second, it conceptualizes a holistic framework, the CyFL Matrix, and outlines a guideline to analyze how the functionalities of a CPPS relate to operational and social sustainability-related performance impacts at different levels of analysis. Finally, it presents an industrial use case, which the CyFL Matrix and the related guidelines are applied to. In doing so, the study offers first support to researchers and managers of manufacturing companies willing to define suitable operational and social sustainability-related performances for Human-centric Cyber-Physical Production Systems of the future

Rare Copy Number Variants in \u3cem\u3eNRXN1\u3c/em\u3e and \u3cem\u3eCNTN6\u3c/em\u3e Increase Risk for Tourette Syndrome

Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal development and/or maintenance of cortico-striato-thalamo-cortical circuits. TS is highly heritable, but its underlying genetic causes are still elusive, and no genome-wide significant loci have been discovered to date. We analyzed a European ancestry sample of 2,434 TS cases and 4,093 ancestry-matched controls for rare (\u3c 1% frequency) copy-number variants (CNVs) using SNP microarray data. We observed an enrichment of global CNV burden that was prominent for large (\u3e 1 Mb), singleton events (OR = 2.28, 95% CI [1.39–3.79], p = 1.2 × 10−3) and known, pathogenic CNVs (OR = 3.03 [1.85–5.07], p = 1.5 × 10−5). We also identified two individual, genome-wide significant loci, each conferring a substantial increase in TS risk (NRXN1 deletions, OR = 20.3, 95% CI [2.6–156.2]; CNTN6 duplications, OR = 10.1, 95% CI [2.3–45.4]). Approximately 1% of TS cases carry one of these CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS

US Cosmic Visions: New Ideas in Dark Matter 2017: Community Report

This white paper summarizes the workshop "U.S. Cosmic Visions: New Ideas in Dark Matter" held at University of Maryland on March 23-25, 2017.Comment: 102 pages + reference

Recommended standards for conducting and reporting ethnopharmacological field studies

Ethnopharmacological relevance: What are the minimum methodological and conceptual requirements for an ethnopharmacological field study? How can the results of ethnopharmacological field studies be reported so that researchers with different backgrounds can draw on the results and develop new research questions and projects? And how should these field data be presented to get accepted in a scientific journal, such as the Journal of Ethnopharmacology? The objective of this commentary is to create a reference that covers the basic standards necessary during planning, conducting and reporting of field research. Materials and methods: We focus on conducting and reporting ethnopharmacological field studies on medicinal plants or materia medica and associated knowledge of a specific people or region. The article highlights the most frequent problems and pitfalls, and draws on published literature, fieldwork experience, and extensive insights from peer-review of field studies. Results: Research needs to be ethical and legal, and follow local and national regulations. Primary ethnopharmacological field data need to be collected and presented in a transparent and comprehensible way. In short this includes: 1) Relevant and concise research questions, 2) Thorough literature study encompassing all available information on the study site from different disciplines, 3) Appropriate methods to answer the research questions, 4) Proper plant use documentation, unambiguously linked to voucher specimens, and 5) Qualitative and quantitative analyses of the collected data, the latter relying on use-reports as basic units. Conclusion: Although not exhaustive, we provide an overview of the necessary main issues to consider for field research and data reporting including a list of minimal standards and recommendations for best practices. For methodological details and how to correctly apply specific methods, we refer to further reading of suggested textbooks and methods manuals

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

BACKGROUND: Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer. METHODS: A multi-national, open-label, controlled, randomized, parallel-group, phase II pilot study was conducted in 20 centers in 7 countries. Cilengitide was administered at 600 mg/m(2 )twice weekly for 4 weeks per cycle and gemcitabine at 1000 mg/m(2 )for 3 weeks followed by a week of rest per cycle. The planned treatment period was 6 four-week cycles. The primary endpoint of the study was overall survival and the secondary endpoints were progression-free survival (PFS), response rate, quality of life (QoL), effects on biological markers of disease (CA 19.9) and angiogenesis (vascular endothelial growth factor and basic fibroblast growth factor), and safety. An ancillary study investigated the pharmacokinetics of both drugs in a subset of patients. RESULTS: Eighty-nine patients were randomized. The median overall survival was 6.7 months for Cilengitide and gemcitabine and 7.7 months for gemcitabine alone. The median PFS times were 3.6 months and 3.8 months, respectively. The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively. Changes in the levels of CA 19.9 went in line with the clinical course of the disease, but no apparent relationships were seen with the biological markers of angiogenesis. QoL and safety evaluations were comparable between treatment groups. Pharmacokinetic studies showed no influence of gemcitabine on the pharmacokinetic parameters of Cilengitide and vice versa. CONCLUSION: There were no clinically important differences observed regarding efficacy, safety and QoL between the groups. The observations lay in the range of other clinical studies in this setting. The combination regimen was well tolerated with no adverse effects on the safety, tolerability and pharmacokinetics of either agent